OB
Ollin Biosciences
United States · Biotech · Healthtech · Enterprise software
Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series B | $330M | a16z Bio+Health — Role not disclosedARCH Venture Partners — Role not disclosedBlackstone Multi-Asset Investing — Role not disclosedCanada Pension Plan Investment Board — Role not disclosedCommodore Capital — Role not disclosedMonograph Capital — Role not disclosedMubadala Capital — Role not disclosedRA Capital Management — Role not disclosedTCGX — Role not disclosedT. Rowe Price Investment Management — Role not disclosed |